“VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers” Report Now Available at MarketPublishers.com

17 Oct 2011 • by Natalie Aster
“VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers” Report Now Available at MarketPublishers.com

LONDON – Vascular Endothelial Growth Factor (VEGF) is the most prominent inducer of angiogenesis. It undergoes a careful study and is observed in a number of cancers. Treatment VEGFs via inhibition of such VEGFs as bevacizumab (Avastin®) turned into a standard for a large fraction of cancers. Nevertheless, the therapy is not applicable to all types of the disease and patients. This results in a necessity of biomarkers usage, enabling to indicate patients who may undertake such therapy.

New research report “VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011” developed by Biopharm Reports has been recently published by Market Publishers Ltd.

Report Details:

Title: VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011
Published: October, 2011
Pages: 97
Price: US$ 1,520

The report provides vital information on biomarkers indentified amid patients receiving VEG-inhibitor therapies, including their description and explanation. The research offers full coverage of over ten cancers and indicates and classifies associations of drug types together with comparative therapies. Besides, clinical trial findings can also be found in the study.

Report Contents:

EXECUTIVE SUMMARY

CHAPTER 1: BACKGROUND (P.18)

1.1 VEGF Inhibition

1.2 Bevacizumab

1.3 Biomarkers

1.4 This Report

CHAPTER 2 COLORECTAL CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P. 22)

Summary

2.1 Introduction

2.2 Glycoprotein

2.3 Protein

2.4 Protein

2.5 Cells

2.6 Genetic

2.7 Physical

2.8 Genetic

2.9 Protein

2.10 Proteins

2.11 Proteins and Genetic

2.12 Image

2.13 Proteins

2.14 Protein

CHAPTER 3 BREAST CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.42)

Summary

3.1 Introduction

3.2 Protein

3.3 Protein

3.4 Protein

3.5 Protein

3.6 Protein

3.7 Genetic

3.8 Protein

CHAPTER 4 RENAL CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.50)

Summary

4.1 Introduction

4.2 Image

4.3 Protein

4.4 Physical

4.5 Protein

4.6 Body Characteristic

CHAPTER 5 OVARIAN CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.55)

Summary

5.1 Introduction

5.2 Proteins

5.3 Proteins

5.4 Proteins

5.5 Proteins

CHAPTER 6 LUNG CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.60)

Summary

6.1 Introduction

6.2 Physical Parameter

6.3 Protein

6.4 Genetic

6.5 Protein

CHAPTER 7 LIVER CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.65)

Summary

7.1 Introduction

7.2 Protein

7.3 Image

CHAPTER 8 OTHER CANCERS: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.71)

Summary

8.1 Introduction

8.2 Proteins

8.3 Proteins

8.4 Protein

8.5 Protein

8.6 Physical

8.7 Physical

8.8 Physical

CHAPTER 9: DISCUSSION (P.80)

9.1 Overview

9.2 Colorectal Cancer

9.3 Breast Cancer:

9.4 Renal Cancer:

9.5 Ovarian Cancer

9.6 Lung Cancer

9.7 Liver Cancer

9.8 Other Cancers

9.9 Conclusions

 

TABLES

Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

 

FIGURES

Figure 9.1 Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.2 Cancer types evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.3 Author countries (identified in this report) of cancers evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

More new market research reports by the publisher can be found at Biopharm Reports page.

 

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com